Loriot, Y., Powles, T., Moreno, V., Kang, T. W., Cicin, I., Girvin, A., Akapame, S., O'Hagan, A., Zhu, W., Tammaro, M., Thomas, S., Triantos, S., Siefker-Radtke, A. O. (2026). Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00826